Back to Search
Start Over
PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
- Source :
- Einstein (São Paulo), Vol 10, Iss 4, Pp 526-527
- Publisher :
- Instituto Israelita de Ensino e Pesquisa Albert Einstein.
-
Abstract
- This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.
- Subjects :
- dislipidemias
lipoproteínas
ldl-colesterol
Medicine
Subjects
Details
- Language :
- English, Portuguese
- ISSN :
- 16794508 and 23176385
- Volume :
- 10
- Issue :
- 4
- Database :
- Directory of Open Access Journals
- Journal :
- Einstein (São Paulo)
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.93ad9ab7be404629a2055e56fdfe21d3
- Document Type :
- article
- Full Text :
- https://doi.org/10.1590/S1679-45082012000400024